Stay updated on DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial

Sign up to get notified when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The revision tag was updated to v3.6.3 from v3.6.2, reflecting a small maintenance update.
    Difference
    0.0%
    Check dated 2026-07-04T13:17:09.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now displays a newer revision tag (v3.6.2) replacing the previous v3.6.0. This indicates a minor software update applied to the page.
    Difference
    0.0%
    Check dated 2026-06-27T07:41:22.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The study page now indicates that enrollment has closed, and additional help/navigation sections such as How to Read a Study Record, Common Questions, and How to Join a Study were added.
    Difference
    0.4%
    Check dated 2026-06-13T00:28:29.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    A new revision tag indicates a minor update to the site or content management system. It signals behind-the-scenes maintenance without altering the displayed study details or page behavior.
    Difference
    0.0%
    Check dated 2026-06-05T22:11:33.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Revision updated from v3.5.3 to v3.5.4. This indicates a minor documentation/versioning update rather than changes to the study data or displayed content.
    Difference
    0.0%
    Check dated 2026-05-15T15:35:31.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Results were posted on 2026-05-06 for the SPiReL trial, with detailed efficacy and safety outcomes. The update includes measures such as Objective Response Rate, Duration of Response, Time to Next Treatment, and related biomarker analyses.
    Difference
    2%
    Check dated 2026-05-08T12:12:03.000Z thumbnail image

Stay in the know with updates to DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.